Medical Grade GLP-1 Peptide Providers in Florida

Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery | Last updated: June 28, 2026

Key Takeaways

• Medical-grade GLP-1 providers in Florida must hold active state licensure, source from 503A or 503B compounding pharmacies, and use batch-tested products with Certificates of Analysis.
• Florida regulations require a valid patient-provider relationship, including thorough intake and lab review, before any GLP-1 or GLP-3R prescription.
• Compounded GLP-1 peptides allow flexible dosing but require verified pharmacy standards and ongoing clinical monitoring for safe, effective use.
• GLP-3R formulations may reduce gastrointestinal side effects and help preserve lean muscle compared with earlier GLP-1 agonists, while still needing rigorous provider oversight.
• Patients seeking personalized, lab-driven GLP-1 or GLP-3R protocols can schedule a consultation at Mirror Plastic Surgery for concierge-level care across Florida.

Florida Rules for Medical-Grade GLP-1 and GLP-3R in 2026

In Florida, any provider who prescribes or dispenses peptide therapy, including GLP-1 and GLP-3R compounds, must hold a valid state medical license. The Florida Board of Medicine and the Florida Board of Nursing govern prescriptive authority for physicians and advanced practice registered nurses (APRNs). Nurse practitioners who practice under a collaborative agreement with a supervising physician hold prescriptive authority under Florida Statute §464.012.

Compounded GLP-1 peptides sit in a distinct regulatory category. The FDA distinguishes between 503A pharmacies, which compound for individual prescriptions, and 503B outsourcing facilities, which produce larger batches under current Good Manufacturing Practice standards. Florida providers who use either option must verify that the pharmacy holds proper state and federal registrations.

Since 2025, FDA enforcement around compounded semaglutide and tirzepatide has intensified after official drug shortages resolved. Providers who continued dispensing compounded versions after shortage removal received warning letters. In 2026, Florida clinics must confirm that any compounded GLP-1 analog they prescribe falls within a currently recognized shortage or qualifies under documented clinical differentiation. That determination requires active, licensed oversight and ongoing review, not a one-time prescription.

Telehealth prescribing of controlled and non-controlled compounds across Florida remains permitted under Florida Statute §456.47, as long as a valid patient-provider relationship exists before prescribing. This relationship includes a thorough intake, medical history review, and often a lab panel, not a brief online questionnaire.

Comparing FDA-Approved and Compounded GLP-1 Peptides

FDA-approved GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) have completed Phase III clinical trials that demonstrate efficacy and safety for specific indications. Their manufacturing follows cGMP oversight, and each lot undergoes testing for identity, potency, and sterility before release.

Compounded GLP-1 peptides are not FDA-approved products. Licensed compounding pharmacies, either 503A or 503B, prepare them based on valid prescriptions. The key quality factor is whether the pharmacy performs independent third-party batch testing and provides a Certificate of Analysis for every lot. Without a COA, a provider cannot confirm that the compound contains the labeled active ingredient at the stated concentration.

Key distinctions between the two categories include the following:

• FDA-approved: Standardized dosing, pre-filled delivery devices, manufacturer-backed pharmacovigilance, and potential insurance coverage pathways.
• Compounded (503A/503B): Customizable dosing and formulation, no FDA pre-market approval, and quality that depends entirely on pharmacy standards and provider verification.

A medically supervised compounded protocol can provide dosing flexibility that branded products do not offer. This flexibility matters when titrating for tolerability or combining with complementary peptides. That benefit only becomes a clinical advantage when the provider has verified the pharmacy’s COA, sterility testing records, and state licensure.

GLP-3R Benefits Compared With Earlier GLP-1s

Within the compounded peptide category, GLP-3R represents a newer generation of receptor-targeted formulations designed to address limitations seen with first-generation GLP-1 receptor agonists. GLP-1 agonists primarily act on the glucagon-like peptide-1 receptor to suppress appetite and improve insulin secretion. GLP-3R compounds are engineered to engage a broader receptor profile, which clinical observers associate with a more favorable side-effect pattern.

Reported advantages of GLP-3R formulations include the following:

• Reduced gastrointestinal burden: Nausea, vomiting, and constipation, the most common adverse effects with GLP-1 agonists, appear less pronounced in early GLP-3R observations.¹
• Muscle preservation: GLP-1-driven weight loss carries a documented risk of lean mass reduction alongside fat loss. GLP-3R formulations are being studied for their potential to lessen this muscle-wasting effect, which matters for patients with sarcopenia risk or active fitness goals.¹
• Broader metabolic indications: GLP-3R compounds show early promise for insulin resistance, cardiovascular risk factor reduction, and inflammatory metabolic pathways, which extends the clinical rationale beyond weight management alone.

Because GLP-3R is a compounded formulation rather than an FDA-approved drug, its use requires the same rigorous provider framework as other compounded peptides. That framework includes a licensed prescriber, a verified 503A or 503B pharmacy, batch-tested product, and ongoing lab monitoring. Providers who offer GLP-3R without this infrastructure are not operating at a medical-grade standard.

How Mirror Plastic Surgery Designs Peptide Protocols

At Mirror Plastic Surgery, Ellie Pranckevicius, FNP-BC, leads all peptide therapies. Ellie earned her Bachelor’s in Health Science from Boston University on the premedical track and completed both her BSN and MSN at the University of South Florida. Before nurse practitioner training, she spent four years in the Neuroscience ICU at Tampa General Hospital, which sharpened her understanding of metabolic physiology, drug interactions, and systemic recovery. Her combined background in aesthetics licensure and critical-care nursing allows her to evaluate both cosmetic goals and underlying physiology for each patient.

The evaluation process follows a structured concierge model that keeps safety and personalization at the center.

1. 30–60 minute consultation: Ellie reviews full medical history, current medications, lifestyle factors, and goals.
2. Lab panel review: Thyroid, liver, kidney, diabetes markers, and hormone panels are reviewed or ordered. For GLP-1 and GLP-3R candidates, metabolic and cardiovascular markers receive priority.
3. Custom protocol design: Peptide selection, dosing, and titration schedule are built around the individual’s lab results and clinical picture, not a preset template.
4. Written and video instructions: Reconstitution, self-administration technique, and storage are covered in detail before the first dose.
5. Ongoing support: Ellie remains accessible by direct text and scheduled telemedicine appointments throughout the protocol, with lab rechecks at clinically appropriate intervals.

Book an appointment with Ellie to start a lab-informed GLP-1 or GLP-3R evaluation.

Provider Verification Checklist for Florida Patients

Before committing to any Florida peptide provider, use this checklist to confirm that the clinic meets medical-grade standards for licensure, pharmacy sourcing, product testing, and clinical oversight.

Criterion	What to Verify	How to Confirm	Mirror Plastic Surgery
Florida Medical Licensure	Active MD, DO, or APRN license with prescriptive authority	Florida MQA license lookup	Ellie Pranckevicius, FNP-BC, board-certified, active Florida license
503A/503B Pharmacy Relationship	Documented sourcing from a registered compounding pharmacy	Ask for pharmacy name and FDA or state registration number	Sourced from verified, registered compounding pharmacies
Batch Testing / Certificate of Analysis	Third-party COA confirming identity, potency, and sterility per lot	Request a COA for the specific lot dispensed	Batch-tested products with COA available
Lab-Based Personalization	Metabolic, hormonal, and organ-function labs reviewed before prescribing	Ask whether labs are required or optional	In-depth lab panel review standard for GLP-1 and GLP-3R protocols
Ongoing Clinical Supervision	Direct practitioner access between appointments and protocol adjustment capability	Ask how and when you can reach your provider	Direct text access to Ellie and scheduled telemedicine follow-ups

Red Flags When Choosing a Florida Peptide Clinic

Several patterns signal that a provider is not operating at a medical-grade standard. These red flags fall into three groups: clinical shortcuts that bypass safety checks, documentation gaps that block quality verification, and regulatory problems that suggest systemic risk.

Clinical shortcuts:

• No lab requirement before prescribing GLP-1 or GLP-3R: Metabolic peptides carry risks for patients with undiagnosed thyroid disease, pancreatitis history, or renal impairment. Skipping labs reflects a shortcut, not a convenience.
• No follow-up protocol: GLP-1 and GLP-3R therapies need titration, monitoring for adverse effects, and periodic lab rechecks. A provider who dispenses without a structured follow-up plan is not practicing at a medical-grade level.

Documentation gaps:

• No Certificate of Analysis provided on request: Any provider who cannot or will not share batch-testing documentation for the specific lot dispensed cannot verify what they are prescribing.
• Pharmacy sourcing is unverifiable: If a provider cannot name the compounding pharmacy or confirm its 503A or 503B registration, product quality remains uncertain.

Regulatory non-compliance:

• Prescription issued after a brief online questionnaire only: A valid patient-provider relationship under Florida law requires a thorough intake. A checkbox form does not meet that standard.
• No named licensed prescriber: If a clinic cannot identify the specific licensed practitioner responsible for your prescription, that gap creates both regulatory and safety concerns.

Statewide Telehealth Access to Peptide Care

Mirror Plastic Surgery serves patients across Florida, from Miami to Jacksonville and Orlando to Pensacola, through a fully compliant telehealth model. Under Florida’s telehealth statute, the consultation, lab review, protocol design, and follow-up care can all occur remotely. Compounded peptides ship directly to the patient from the dispensing pharmacy after the prescription is issued.

Patients outside the Tampa Bay area who cannot visit the St. Petersburg office in person receive the same concierge standard. Ellie completes a full intake, reviews lab panels, provides written and video administration instructions, and remains available by direct text throughout the protocol. Physical distance does not reduce clinical rigor.

Patients who prefer in-person care can visit Mirror Plastic Surgery at 780 4th Ave S, St. Petersburg, FL 33701. Appointments can be secured by calling or texting 727-361-6515.

Book an appointment with Ellie whether you are in Tampa Bay or anywhere else in Florida. The full concierge evaluation remains available statewide.

Frequently Asked Questions

Are GLP-1 and GLP-3R peptides legal to prescribe in Florida in 2026?

Yes, when providers follow specific rules. A licensed Florida physician or APRN with prescriptive authority can legally prescribe compounded GLP-1 and GLP-3R peptides when they come from a registered 503A or 503B compounding pharmacy and are based on a valid patient-provider relationship. The regulatory landscape has tightened since 2025, especially around compounded semaglutide, so the prescribing provider must confirm that the compound qualifies under current FDA shortage or clinical differentiation criteria. Providers who lack active licensure or verified pharmacy relationships are not compliant.

What is the difference between a 503A and a 503B compounding pharmacy?

A 503A pharmacy compounds medications for individual patients based on specific prescriptions. It is regulated mainly at the state level and does not require FDA registration, although it must comply with USP standards. A 503B outsourcing facility produces larger batch quantities under FDA oversight and current Good Manufacturing Practice standards, which include more rigorous sterility and potency testing. Both can serve as legitimate sources for compounded GLP-1 peptides, but the provider must verify the pharmacy’s registration and request a Certificate of Analysis for every lot dispensed.

How long does it take to see results from a GLP-1 or GLP-3R protocol?

Timelines vary by individual, starting dose, and target outcome. Some patients notice changes in appetite regulation and water retention within the first week.¹ Meaningful changes in body composition, metabolic markers, or inflammatory indicators usually appear over four to twelve weeks of consistent use with appropriate titration.¹ Lab rechecks at six to twelve weeks provide objective data on metabolic response. Results differ from person to person because genetics, diet, activity level, and baseline health status all influence outcomes.¹ A personalized protocol built on lab data generally outperforms a standardized dose approach.

What happens if I stop GLP-1 or GLP-3R therapy?

The physiological effects of GLP-1 and GLP-3R peptides do not last permanently. Appetite regulation, insulin sensitivity improvements, and weight management benefits typically fade after discontinuation.¹ The rate of reversal depends on whether underlying metabolic drivers were addressed through lifestyle changes during the protocol. Many patients use a maintenance protocol, often at a lower dose or reduced frequency, to sustain outcomes. Ellie reviews each patient’s lab trends and clinical response to decide whether a maintenance phase makes sense and how it should look for that individual.

Can I access Mirror Plastic Surgery’s peptide services if I live outside Tampa Bay?

Yes. Mirror Plastic Surgery offers a fully compliant telehealth model for Florida residents statewide. The consultation, lab review, protocol design, and follow-up care occur remotely, and compounded peptides ship directly from the dispensing pharmacy. Patients in all Florida counties, as well as eligible patients in other U.S. states, can access the same concierge standard of care that in-person patients receive. The intake process remains identical, with a full medical history review, lab panel evaluation, and a custom protocol built around individual physiology and goals.

Is a lab panel always required before starting a GLP-1 or GLP-3R protocol?

For GLP-1 and GLP-3R therapies, lab review forms a standard part of the Mirror Plastic Surgery intake process. Metabolic peptides carry meaningful risks for patients with undiagnosed thyroid pathology, pancreatitis history, hepatic or renal impairment, or uncontrolled diabetes. Reviewing thyroid, liver, kidney, and glucose metabolism markers before prescribing provides the clinical basis for safe dosing and appropriate patient selection. If a patient arrives without recent labs, Ellie orders them before finalizing any protocol.

What makes GLP-3R different from the GLP-1 medications I have heard about?

GLP-1 receptor agonists like semaglutide act mainly on a single receptor pathway to suppress appetite and improve insulin secretion. GLP-3R formulations are designed to engage a broader receptor profile, which early clinical observations associate with reduced gastrointestinal side effects, better lean muscle preservation during weight loss, and a wider range of metabolic indications, including cardiovascular risk factors and insulin resistance. GLP-3R is a compounded formulation, not an FDA-approved drug, so it demands the same medical-grade oversight described earlier in this article.

Disclaimer: Compounded GLP-1 and GLP-3R peptides are not FDA-approved for all uses described. The information in this article is educational and does not constitute medical advice. Individualized medical supervision by a licensed practitioner, including appropriate laboratory evaluation and ongoing monitoring, is essential before initiating any peptide therapy.

---